2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Thursday, April 30, 2020

5:10PM-5:40PM: Abstract Number: 021

Myositis Autoantibodies in a Racially Diverse Population of Children with Idiopathic Inflammatory Myopathies

Poster Breakout 3 – Scleroderma, Myositis, & Miscellaneous

5:10PM-5:40PM: Abstract Number: 015

Normal MRI Appearance of Marrow Adjacent to the Sacroiliac Joints in Healthy Children During Development

Poster Breakout 1 – Advances in Diagnosis & Classification

5:10PM-5:40PM: Abstract Number: 012

Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases

Poster Breakout 1 – Advances in Diagnosis & Classification

5:10PM-5:40PM: Abstract Number: 014

Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis

Poster Breakout 1 – Advances in Diagnosis & Classification

6:00PM-7:00PM: Abstract Number: 053

Acceptability and Usability Testing of a Preliminary Version of the JIA Option Map, an Electronic Decision Aid for Pain Management Options in Juvenile Idiopathic Arthritis

Poster Session 1

6:00PM-7:00PM: Abstract Number: 169

Addressing the Pediatric Rheumatology Workforce Shortage: Is Early Exposure Enough?

Poster Session 1

6:00PM-7:00PM: Abstract Number: 072

Allogenic Hematopoietic Stem Cell Transplantation for Refractory Childhood Rheumatic Diseases

Poster Session 1

6:00PM-7:00PM: Abstract Number: 041

Ancestry, Demographic and Clinical Features of Israeli Periodic Fever Aphthous Stomatitis, Pharyngitis and Adenitis (PFAPA) Syndrome – a Multi-center Cohort

Poster Session 1

6:00PM-7:00PM: Abstract Number: 066

Baseline Kidney Biopsy in Lupus Patients Without Renal Manifestations. Underappreciated or Overrated?

Poster Session 1

6:00PM-7:00PM: Abstract Number: 059

Challenges Faced by Families of Children with an Auto-inflammatory Disease

Poster Session 1

6:00PM-7:00PM: Abstract Number: 054

Clinical and Laboratory Characteristics in Juvenile-onset Systemic Lupus Erythematosus Across Age Groups

Poster Session 1

6:00PM-7:00PM: Abstract Number: 170

Clinical Team Perspectives on the Transition from Pediatric to Adult Care for Patients with Childhood-Onset SLE

Poster Session 1

6:00PM-7:00PM: Abstract Number: 171

Development and Acceptability of an Adolescent Self-management Program for Juvenile Idiopathic Arthritis

Poster Session 1

6:00PM-7:00PM: Abstract Number: 068

Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus

Poster Session 1

6:00PM-7:00PM: Abstract Number: 151

Differences in Chromatin Architecture Between Treatment-Naïve Pediatric and Adult Lupus Patients

Poster Session 1

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].